136 related articles for article (PubMed ID: 38117102)
1. Editorial Comment: FDG PET/CT Has Impact in Chimeric Antigen Receptor T-Cell Therapy Response Assessment and Outcome Prediction.
Marcus C
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330703. PubMed ID: 38117102
[No Abstract] [Full Text] [Related]
2.
Ruff A; Ballard HJ; Pantel AR; Namoglu EC; Hughes ME; Nasta SD; Chong EA; Bagg A; Ruella M; Farwell MD; Svoboda J; Sellmyer MA
Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
[TBL] [Abstract][Full Text] [Related]
3. Early Hyperprogression of Lymphoma Detected by 18 F-FDG PET/CT After Chimeric Antigen Receptor T-Cell Therapy.
He L; Deng Y; Deng Y; Xie H; Zhang W
Clin Nucl Med; 2023 Mar; 48(3):256-258. PubMed ID: 36634320
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T-Cell Therapy of Neurolymphomatosis Monitored by FDG PET/CT.
Li S; Wang H; Wang G; Lu X; Yang J
Clin Nucl Med; 2023 May; 48(5):445-447. PubMed ID: 36716490
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma.
Bailly C; Carlier T; Tessoulin B; Gastinne T; Kraeber-Bodere F; Le Gouill S; Bodet-Milin C
Hematol Oncol; 2022 Oct; 40(4):796-800. PubMed ID: 35044695
[No Abstract] [Full Text] [Related]
6. 2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS.
Paccagnella A; Farolfi A; Casadei B; Garibotto V; Zinzani P; Fanti S
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1090-1091. PubMed ID: 34550427
[No Abstract] [Full Text] [Related]
7. Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts.
Murad V; Kohan A; Ortega C; Prica A; Veit-Haibach P; Metser U
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330301. PubMed ID: 38054958
[TBL] [Abstract][Full Text] [Related]
8. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion.
Cohen D; Beyar-Katz O; Even-Sapir E; Perry C
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2447-2449. PubMed ID: 35146579
[No Abstract] [Full Text] [Related]
9. Can Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predict Chimeric Antigen Receptor T Cell Adverse Effects?
Wang J; Galal A
Biol Blood Marrow Transplant; 2019 Jun; 25(6):e187-e188. PubMed ID: 31075397
[No Abstract] [Full Text] [Related]
10.
Derlin T; Schultze-Florey C; Werner RA; Möhn N; Skripuletz T; David S; Beutel G; Eder M; Ross TL; Bengel FM; Ganser A; Koenecke C
Ann Nucl Med; 2021 Jan; 35(1):132-138. PubMed ID: 33174144
[TBL] [Abstract][Full Text] [Related]
11. New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy.
Wang G; Yang X; Wang H; Wang W; Yang J
Clin Nucl Med; 2023 Jul; 48(7):647-649. PubMed ID: 37083630
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
13. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
15. [
Cohen D; Luttwak E; Beyar-Katz O; Hazut Krauthammer S; Bar-On Y; Amit O; Gold R; Perry C; Avivi I; Ram R; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):953-962. PubMed ID: 34480603
[TBL] [Abstract][Full Text] [Related]
16. [Roles of PET/CT in Predicting the Prognosis of Diffuse Large B Cell Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy].
Zheng XQ; Ding CY; Zou YX; Zhu HY; Wang L; Fan L; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1189-1196. PubMed ID: 32798397
[TBL] [Abstract][Full Text] [Related]
17. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
[TBL] [Abstract][Full Text] [Related]
18. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
[TBL] [Abstract][Full Text] [Related]
19. Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma.
Boursier C; Perrin M; Bordonne M; Campidelli A; Verger A
Clin Nucl Med; 2022 Feb; 47(2):e152-e153. PubMed ID: 34406181
[TBL] [Abstract][Full Text] [Related]
20. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]